Keith Lenden is a seasoned venture partner at ARCH Venture Partners since June 2017, specializing in biotechnology and pharmaceuticals. As a co-founder of multiple companies including Autobahn Therapeutics, Boundless Bio, and Abide Therapeutics, Lenden has significantly contributed to drug discovery and development in various fields such as CNS and oncology. Previous roles include co-founding Receptos, which was acquired by Celgene, and holding executive positions at Esperion Therapeutics and Maxygen, focusing on corporate development and business strategy. Lenden's academic background includes an MBA from the University of California, Berkeley, and a BE and BA in Engineering from Dartmouth College. Additionally, Lenden was recognized as a Kauffman Fellow from 2011 to 2013.
This person is not in the org chart
This person is not in any teams
This person is not in any offices